VANCOUVER, Washington, January 8, 2025 (GLOBE NEWSWIRE) — Absci Company (NASDAQ: ABSI), a data-driven generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including advanced Absci capabilities new Antibody design models. AMD will also invest $20 million in Absci, structured as a private investment in public equity (PIPE), highlighting the growing demand for innovative AI applications in drug discovery.
The strategic partnership supports Absci’s mission to create better biologics for patients faster by providing optimized AI solutions for complex biological modeling that deliver exceptional performance, reduced infrastructure costs and faster production cycles. faster innovation. Absci Founder and CEO Sean McClain will discuss the strategic partnership at the 43rd Annual JPMorgan Healthcare Conference on Wednesday, January 15 at 4:30 p.m. PT. Absci and AMD will showcase the exceptional performance of AMD’s Instinct accelerators in processing complex biological applications, including Absci’s proprietary IgDesign1 model, the first in vitro validated reverse folding model for antibody design.
“At Absci, we are always looking for ways to push the boundaries of what is possible in drug discovery,” said Sean McClain, founder and CEO of Absci. “This partnership with AMD gives us the unique advantage of working closely with a partner deeply committed to meeting our needs while providing the most effective and innovative AI solutions available. AMD’s high-performance computing will enable us to continue developing the next technologies. generation of therapeutic antibodies, and we are excited about the potential this partnership holds to accelerate the future of drug discovery.
“We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate therapeutic breakthroughs and transform the way biologic medicines are developed,” said Mark Papermaster, executive vice president and chief technology officer of AMD. . “Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software designed for the most demanding AI workloads.
About Absci
Absci is a data-driven, generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients faster. OUR Integrated drug creation™ unlocks the potential to accelerate time to clinic and increase the likelihood of success by simultaneously optimizing multiple drug characteristics important for both development and therapeutic benefits. With the data to train, the AI to build, and the wet lab to validate, we can screen billions of cells per week, allowing us to move from AI-designed candidates to wet-lab-validated candidates in as much time as possible. just six weeks. Absci is headquartered in Vancouver, Washington, with our AI research lab in New York and an innovation center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci),@Abscibio), And YouTube.
About AMD
For more than 50 years, AMD has been at the forefront of innovation in high-performance computing, graphics and visualization technologies. Billions of people, Fortune 500 companies and leading scientific research institutions around the world rely on AMD technology every day to improve the way they live, work and play. AMD employees are focused on creating leading, high-performance, adaptive products that push the boundaries of what is possible. For more information on how AMD is enabling today and inspiring tomorrow, visit AMD (NASDAQ: AMD) website, blog, LinkedIn And X pages.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “continue,” “anticipate,” “plan,” “believe,” “ aims”, “potential”, “forecast”, “estimates”, “extends”, “expects” and “intends” or similar expressions. Absci intends that these forward-looking statements, including express or implied statements regarding the acceleration of the future of AI drug discovery, Absci’s leadership in AI drug discovery, the ability to ‘Absci to leverage AMD’s stock investment and Absci’s ability to create better biologics and develop next-generation antibody therapeutics, among others, are to be covered by the safe harbor provisions for the forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and Absci makes this statement for purposes of complying with these safe harbor provisions. These forward-looking statements reflect Absci’s current beliefs about its plans, intentions, expectations, strategies and prospects, which are based on information currently available to it and assumptions made by Absci. Absci can give no assurance that the plans, intentions, expectations or strategies will be achieved or achieved, and further, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond the control of Absci, including, without limitation, risks and uncertainties relating to Absci’s ability to leverage AMD’s investment, to collaborate effectively in research, discovery and drug development with partners or potential partners, Absci’s dependence on third parties. to support its internal development programs, including for the manufacture and provision of preclinical and clinical supplies of its product candidates or their components, the ability and willingness of its existing and potential partners to pursue the development and commercialization of programs or product candidates under the terms of Absci’s partnership agreements, general market conditions and regulatory developments likely to affect the activities of Absci and its partners under these agreements, as well as the risks stated in periodic reports Absci’s most recent filings with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in subsequent filings with the U.S. Securities and Exchange Commission -United. Except as required by law, Absci undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact investors Absci
Alex Khan
Vice President, Finance and Investor Relations
[email protected]
Media contact Absci
[email protected]
Investor relations:
Matt Ramsay
AMD Investor Relations
[email protected]
AMD Media Contact
Brandi Martina
AMD Communication
[email protected]
